Accuracy of healthcare systems data for identifying cardiovascular outcomes after stroke due to intracerebral haemorrhage in the United Kingdom.
Hosking A. et al, (2024), Trials, 25
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Nephrol Dial Transplant
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study.
Mihaylova B. et al, (2024), Lancet Reg Health Eur, 40
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.
Petrucci G. et al, (2024), Eur Heart J, 45, 1355 - 1367
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ. et al, (2024), J Am Soc Nephrol, 35, 202 - 215
Thromboxane biosynthesis and risk of future events in diabetes mellitus: A sub-study of the ASCEND trial.
PARISH S. et al, (2023), European Heart Journal
Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Baigent C. and Sádaba R., (2023), Eur Heart J
Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Baigent C. and Sádaba R., (2023), Eur J Cardiothorac Surg, 64
Empagliflozin in Patients with Chronic Kidney Disease. Reply.
Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
HERRINGTON W. et al, (2023), Kidney International Reports
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Zhou J. et al, (2023), Pharmacoeconomics
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Chapman D. et al, (2023), Kidney Int
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert M. et al, (2023), European Respiratory Journal, 61
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.
Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Staplin N. et al, (2022), Hypertension, 79, 2671 - 2681
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med